How a rare kidney disease gained a robust new therapy pipeline

Дата публикации: 24-06-2026 13:17:07

In December 2021, the FDA approved the first therapy indicated to treat primary immunoglobulin A nephropathy. Since then, several novel drugs have received accelerated approval for the disease, and more are in the pipeline.“In just the last few years, there’s been an explosion in therapies available to us,” Jackson Kim, MD, clinical assistant professor in the division of nephrology at Stanford Health Care, told Healio.Kim, who graduated from medical school in 2017, said he was taught that immunoglobulin A (IgA) nephropathy “was not a big deal.” The disease progressed slowly, if at all, and

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	IgA nephropathy treatment decisions vary among physicians	0	7	01-07-2026
2	Respiratory failure, CKD-related mortality rose in 1999-2021	0	7	26-06-2026
3	Expect eGFR dips when using blood pressure-lowering medications	0	7	29-06-2026
4	FDA advisory committee for peptides stocked with conflicts of interest	0	5	01-07-2026
5	Q&A: What it takes to run a culinary camp for children with CKD	6	7	26-06-2026
6	Combination GLP-1 and SGLT2 therapy may lower heart risk	0	5	25-06-2026
7	Some adverse pregnancy outcomes tied to kidney donation	0	7	30-06-2026
8	Un nuevo avance para el lupus: llega a España una pluma precargada que puede reducir las visitas al hospital	6	7	17-06-2026
9	В России тестируют два отечественных препарата для лечения редких болезней	0	0	29-02-2020

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 3. Информативность: 7. Источник: www.healio.com.